Abstract：Objective: To study the changes and clinical significance of lipid metabolism and coagulation function in patients with primary chronic kidney disease (CKD). Methods: 120 patients with CKD admitted to the hospital from January 2020 to April 2022 were selected as samples for a cross-sectional study. After admission, blood lipid metabolism indicators such as blood urea nitrogen (BUN), serum creatinine (Scr), total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1) and apoB as well as coagulation function indicators of fibrinogen (FIB), D-dimer (D-D), activated partial thromboplastin time (APTT), fibrinogen degradation product (FDP), thrombin time (TT), prothrombin time (PT) and international normalized ratio (INR) were measured. The patients were divided into the CVD group and the control group according to whether CVD occurred or not. The indicators of the two groups were compared and the Logistic regression model was established, and then the predictive value of the model on CVD risk was analyzed by calibration. Results: 34 cases (28.33%) of 120 patients with CKD were complicated with CVD. The proportion of patients with CKD stage 5 and levels of BUN, Scr, TC, LDL-C, and FIB in the CVD group were higher than those in the control group while the level of HDL-C was lower than that in the control group (P<0.05). CKD staging was negatively correlated with lipid metabolism indicators of HDL-C, apoA1, and apoB (P<0.05), and was positively correlated with coagulation function indicators of PT, FIB, D-D, and INR (P<0.05). Binary Logistic regression analysis showed that TC, HDL-C, and FIB were closely related to CVD in patients with CKD (P<0.05), and the predictive model for the risk of CVD in patients with CKD was shown as logit(P)= -2.864+ 0.571× (TC) -2.748× (HDL-C) +0.620× (FIB). The AUC, sensitivity, and specificity of predicting CVD in patients with CKD were 0.807 (95%CI: 0.725~0.873), 82.35%, and 69.77%. Conclusion: The lipid metabolism and coagulation function of patients with primary CKD are abnormal, and there is a significant correlation with CKD staging. The logistic regression model established based on TC, HDL-C, FIB and other indicators have a good reference value for predicting the risk of CVD in patients with CKD.
罗军, 耿克明, 张赟辉, 汪宏. 原发性慢性肾脏病患者脂质代谢及凝血功能变化及临床意义[J]. 河北医学, 2023, 29(2): 311-317.
LUO Jun, GENG Keming, ZHANG Yunhui, et al. Changes in Lipid Metabolism and Coagulation Function in Patients with Primary Chronic Kidney Disease and Their Clinical Significance. HeBei Med, 2023, 29(2): 311-317.
[1] 上海市肾内科临床质量控制中心专家组.慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J].中华肾脏病杂志,2022,38(5):453-464. [2] Woo KT,Chan CM,Lim C,et al.A global evolutionary trend of the frequency of primary glomerulonephritis over the past four decades[J].Kidney Dis (Basel),2019,5(4):247-258. [3] Jankowski J,Floege J,Fliser D,et al.Cardiovascular disease in chronic Kidney disease:pathophysiological insights and therapeutic options[J].Circulation,2021,143(11):1157-1172. [4] 吴思弦,袁浩,周毅峰,等.血栓弹力图评估慢性肾脏病患者凝血功能及其高凝状态的危险因素[J].南方医科大学学报,2020,40(4):556-561. [5] 中华医学会肾脏病学分会.临床诊疗指南(肾脏病学分册)[M].北京:人民卫生出版社,2011.39-43. [6] Arnett DK,Blumenthal RS,Albert MA,et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease:executive summary:a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J].Am Coll Cardiol,2019,74(10):1376-1414. [7] 张学娟,车若琛,丁桂霞.能量代谢在慢性肾脏病中的研究进展[J].医学综述,2020,26(10):1909-1913,1918. [8] Jabarpour M,Rashtchizadeh N,Ghorbani Haghjo A,et al.Protection of renal damage by HMG-CoA inhibitors:a comparative study between atorvastatin and rosuvastatin[J].Iran Basic Med Sci,2020,23(2):206-213. [9] 倪小秋,包自阳,朱彩凤.伴有血脂异常的老年慢性肾小球肾炎CKD1-2期患者临床及病理分析[J].中国动脉硬化杂志,2020,28(4):322-326. [10] Yelamanchili D,Liu J,Gotto AM Jr,et al.Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo[J].Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(12):158794. [11] 谢晖,沈瀚.慢性肾脏病患者凝血功能变化及高凝状态影响因素分析[J].检验医学,2021,36(5):500-503. [12] Pieters M,Ferreira M,de Maat MPM,et al.Biomarker association with cardiovascular disease and mortality -the role of fibrinogen.A report from the NHANES study[J].Thromb Res,2021,198:182-189. [13] 苏文,李虹伟,李卫萍,等.纤维蛋白原水平对急性心肌梗死患者远期预后的影响[J].中国循环杂志,2021,36(9):858-862.
2023, Vol. 29 
冀公网安备13080202000677号